https://www.selleckchem.com/pr....oducts/pqr309-bimira
TLR7 agonists modulate broad spectrum immune activity and are evaluated in the treatment of human diseases including cancer and chronic viral infection. RO7020531, an oral prodrug of a TLR7 agonist, is in clinical development as part of a curative regimen against chronic hepatitis B. We report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7020531 in Chinese healthy volunteers following single and multiple ascending doses (SAD MAD). PK and PD samples were evaluated from four SAD cohorts a
Like
Comment
Share
